Company Statements, Study Results, Stock Movements, Awards and Stock Splits - Research Report on WebMD, Cerner, Waters, Medidata

Company Statements, Study Results, Stock Movements, Awards and Stock Splits -
    Research Report on WebMD, Cerner, Waters, Medidata and Genomic Health

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 18, 2013

NEW YORK, November 18, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting WebMD
Health Corp. (NASDAQ: WBMD), Cerner Corporation (NASDAQ: CERN), Waters
Corporation (NYSE: WAT), Medidata Solutions, Inc. (NASDAQ: MDSO) and Genomic
Health, Inc. (NASDAQ: GHDX). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

WebMD Health Corp. Research Report

On November 13, 2013, WebMD Health Corp (WebMD) released a statement regarding
its editorial integrity. An excerpt from the statement is as follows:
"Consistent with major newspapers, broadcasters and other respected
publishers; WebMD has an editorial organization that produces content in
accordance with well-established editorial policies and practices. The strict
editorial practices we have in place ensure that the content we produce is
unbiased and done so independent of any third party involvement or control.
WebMD also provides advertising and sponsorship opportunities to public and
private sector customers that want to reach our consumer or physician
audiences. When content appearing on WebMD's sites is funded through
advertising or sponsorship, we disclose that funding. As the leading source of
health information, WebMD has an obligation to help our audiences understand
the changing healthcare landscape, which requires us to cover all sides of a
given issue. A review of the content across our consumer and professional
sites demonstrates as much. Our Health Care Reform Center reflects WebMD's
steadfast commitment to editorial integrity, education and trust." The Full
Research Report on WebMD Health Corp. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/c4b8_WBMD

--

Cerner Corporation Research Report

On November 13, 2013, Cerner Corporation's (Cerner) stocks rose 0.55% to
$56.78 at the end of trading. Shares of Cerner slipped 0.46% during the
previous three trading sessions while the NASDAQ composite and Dow rose to
1.18% and 0.38% respectively over the same period. The Full Research Report on
Cerner Corporation - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/83ac_CERN

--

Waters Corporation Research Report

On November 12, 2013, the Waters Corporation (Waters) reported that the
Company has honored the University of Maryland School of Pharmacy (UMSOP) for
its interdisciplinary research using mass spectrometry to discover new and
improved drugs to treat cancer, diabetes and infectious diseases. According to
Waters, the UMSOP Department of Pharmaceutical Sciences' core Mass
Spectrometry Facility under the direction of David Goodlett, PhD, the Isaac E.
Emerson Chair of Pharmaceutical Sciences, is the first such institution which
has been selected for Waters Centers of Innovation Program honors. Waters
added that the honored institution will continue to receive priority access to
new technologies, opportunities to influence the development of
next-generation research instruments, shared opportunities for collaboration
with Waters and priority applications support and funding assistance.
University of Maryland, Baltimore President Jay A. Perman, MD, stated,
"Today's ceremony is a testament to the achievements of this School. Our new
Mass Spectrometry Facility is the largest, most-well equipped and well-staffed
facility of its kind in the Mid-Atlantic region and it will enable us to
shorten the time it takes to translate research findings into new diagnostics,
therapeutics, and preventive procedures that will help patients." The Full
Research Report on Waters Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/2fff_WAT

--

Medidata Solutions Inc Research Report

On November 11, 2013, Medidata Solutions Inc (Medidata) announced that a
two-for-one split of the Company's common stock was approved by its Board of
Directors during the board meeting held on November 7, 2013. According to the
Company, the stock split will be structured in the form of a stock dividend.
The Company stated that the record date for the spilt is December 2, 2013 and
the distribution of the new shares will be made on December 16, 2013 while
trading on a split-adjusted basis is expected to begin on or about December
17, 2013. According to Medidata, the stock split will increase the common
shares outstanding to approximately 53.6 million. The Full Research Report on
Medidata Solutions Inc - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/05dd_MDSO

--

Genomic Health, Inc. Research Report

On November 13, 2013, Genomic Health, Inc. (Genomic Health) reported that the
Journal of Clinical Oncology (JCO) has published positive results from a
large, independent validation study of the Oncotype DX® colon cancer test in
patients from the National Surgical Adjuvant Breast and Bowel Project (NSABP)
C-07 clinical trial. The Company informed that results of the study provide
further confirmation that the Oncotype DX Recurrence Score® (RS) results
predict recurrence risk and provide additional information beyond conventional
risk factors, enabling better discrimination of absolute benefit of
chemotherapy as a function of risk. Genomic Health added that patients with a
high Recurrence Score result can be expected to derive larger absolute
chemotherapy treatment benefit than patients with a low Recurrence Score
result in both stage II and stage III colon cancer. Steven Shak, M.D.,
Executive Vice President of Research and Development, Genomic Health
commented, "With our third published validation study, we continue to
demonstrate that our test provides important quantitative and individualized
risk assessment that helps guide chemotherapy treatment planning and enables
precision medicine." The Full Research Report on Genomic Health, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/db58_GHDX

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.